Good afternoon and welcome to Cara Therapeutics' Third Quarter 2020 Financial Results Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Cara's request. I would now like to turn the call over to the Cara team. Please proceed.

Good afternoon. This is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics' third quarter 2020 financial results and update conference call. The news release became available just after 4:00 P.M. today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing of the data readouts from the company's ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the company's product candidates, including the company's projected timeline for the submission of its first NDA, the potential for the company's product candidates to be alternatives in the therapeutic areas investigated, the potential benefits of Vifor Pharma’s marketing IV KORSUVA in the United States and the company's expected cash reach. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission including the Risk Factors section of the company's most recently quarterly report on Form 10-Q and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements made in today's call speak only as of the date on which they were made. Care Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Participating on today's call are Dr. Derek Chalmers, Cara President and CEO; and Cara Chief Financial Officer, Thomas Reilly. I'll now turn the call over to Dr. Chalmers.

Great. Thank you, Jack. Good afternoon everybody and thanks for joining us today, on this day, that's very special day for our industry and for science in general. We've also been executing on some excellent signs through the third quarter of this year, we've made significant advancements related to our clinical development programs for both KORSUVA Injection and for Oral KORSUVA across a range of pruritic indications. And I'll summarize those programs shortly. In addition, in October, we're very pleased to announce an important commercial license agreement with Vifor Pharma for KORSUVA Injection for the treatment of CKD-associated pruritus specifically in U.S. dialysis patients. We see this as an important strategic deal for the company, which we believe will maximize the potential commercial success for KORSUVA Injection if approved, and I'll cover the terms of this agreement a little later in the call. Additionally, in October, we strengthened our management team by welcoming Thomas Reilly, on the call with me today, as Chief Financial Officer. Tom brings a wealth of experience in biopharma financial strategy from his work at both Allergan and Novartis in the past, and we're very happy to welcome Tom to the team. Due to the ongoing COVID-19 pandemic and in accordance with the FDA's updated guidance for conducting clinical trials, we have implemented numerous clinical and operational measures to prioritize the health and safety of patients, our employees, and study investigators and to minimize potential disruptions to ongoing clinical studies. Due to the entire Cara team's continued dedication and hard work in this area, we remain on track to meet our main clinical and regulatory goals for the year and we continue to enroll patients across all of our ongoing trials. So now let me update you on each of our programs starting with our lead…

Okay. Great, thank you, Derek. Before I begin the financial review, I'd like to say I'm very excited I’ve joined the Cara team. I'm really looking forward to contributing to the financial strategy of the company as we continue to advance our pipeline and focus on several key upcoming milestones that will enhance our long-term value. Now to the financial review. As a reminder, the full financial results for the third quarter 2020 can be found in our press release issued today after the market closed. For the third quarter of 2020, we reported a net loss of $16.5 million or $0.35 per basic and diluted share, compared to a net loss of $32.8 million for $0.74 per basic and diluted share for the same quarter of 2019. In the third quarter of 2020, we recognized revenue of $9.3 million related to the Vifor presenting its collaboration agreement, compared to $5.8 million during the same quarter in 2019. For the third quarter of 2020, we reported R&D expense of $21.1 million, compared to $36 million in the same period of 2019. The lower R&D expenses in the third quarter 2020 were primarily due to a decrease in clinical trial costs, a 2019 $8 million upfront payment upon entering the license agreement with Enteris BioPharma, Inc. and partially offset by $2.5 million milestone earned by Enteris in 2020. G&A expenses were $5.2 million during the third quarter of 2020, compared to $4.2 million in the same period of 2019. The increase in 2020 was primarily due to insurance costs, franchise taxes, payroll related costs, and commercial costs partially offset by decreases in consultants’ costs. Other income was approximately $0.4 million in the third quarter of 2020, compared to approximately $1.3 million in the same period of 2019. The decrease is due to a lower interest income on our investments in marketable securities. As of September 30, 2020, our cash, cash equivalents and marketable securities totaled $131.4 million compared to $218.2 million as of December 31, 2019. The decrease in the balance of cash and cash equivalents, and marketable securities, primarily resulted from cash used in operations. Turning to our financial guidance. Based on projected costs for our clinical development plans and timing expectations, we expect that our current cash, cash equivalents and marketable securities as of September 30, 2020 with the additional funding of $150 million from the Vifor Pharma license agreement in October 2020, will be sufficient to fund our operations into 2023. Not accounting for any potential milestone payments under existing collaborations. With that, I'll turn the call back over to the operator for Q&A.

Thank you. [Operator Instructions] Our first question comes from David Amsellem with Piper Sandler.

This is Zack Sachar on for David. Thank you for taking my questions. Just a couple from me. I know we've asked this in a couple of different ways before, but could you maybe just give us a sense of your updated thoughts on pricing for the IV form? And maybe help us think with that process, what competitors might make sense there? And then quickly on the oral form, could you provide any initial thoughts on the size of the derm force, salesforce that you might plan to be building out? And what kind of spend particularly directed to consumer activities you envision, we're just trying to get a better sense of the cost structure longer-term?

Yes. Hi, Zach. Thank you. I think on latter question, we're a little too far away from in terms of projecting what we're going to be spending on the commercial force there. We’re just concentrating on getting that program into Phase 3 next year. Your question on KORSUVA Injection was related to pricing or possible pricing? I missed that.

Yes. Any thoughts on pricing.

Yes, we're just a little early on that, as we've said on this call, consistently, we're in constant communication with CMS. We believe we have a very good relationship with that group. But we are still a ways away from the labels, it’s just a little early to get into detailed discussion on in terms of pricing for KORSUVA Injection.

Our next question comes from Annabel Samimy with Stifel.

Good afternoon, everyone. This is Nick Rubino on for Annabel. Thanks for taking our questions. Two from us. Now that you have Vifor deal in hand and accompanied capital flexibility, is there anything that you're doing to accelerate the oral program, perhaps opening more sites? And then secondly, you mentioned this new trial in chronic pruritus, I know you're giving later details, but given the population heterogeneity, I guess challenges you saw with predialysis populations, what's your general thinking in approaching this broad chronic pruritus population? I know there is similar protocols you might be considering.

Thanks Nick. On the later question -- let me take that first two. I didn't want to leave the impression we're looking at broad non-specific pruritus of non-specific origin. So that is not what we're going to be looking at in the next Phase 2. It is going to be a very defined patient population, with a very defined pathology associated with that pruritus. So -- and the rationale there in terms of which patient groups we're looking at, as we’ve discussed before, ultimately, we believe that our mechanism of action here is going to be broadly applicable. We're not dependent on blocking any one particular cytokine, or other pruritogen that pops up associated with one specific pathology here. So we'd like to be able to ascertain that we have efficacy in these various pathologies, where we see pruritus as being a real chronic unmet need. And so we kind of satisfied the end organ -- if you like, end organ disease associated pruritus with CKD. As you know, we're looking at dermatological associated pruritus with atopic. And there are some other categories that we'd like to look at specifically, so that at the end of the day when we have that discussion down the road with the FDA, we’ve satisfied that in each of these pathologies which are varied, but all having common and chronic moderate to severe pruritus which is not treatable with current medications that we satisfied that we have efficacy across these areas. So I'm going to be a non-specific pruritus group to look at its going to be sustained pathology for this novel Phase 3 trial that we've been looking at for some time with that strategy in mind. And in terms of our overall capabilities, now you're correct the Vifor deal has certainly dramatically strengthened our balance sheet and we have capability now to push forward with larger trials, I think you're going to see the benefit of that in the Phase 3 trials we plan to initiate in 2021. And there we're hoping to push forwards CKD pre dialysis and assuming positive results, atopic dermatitis into Phase 3. So the advantage we see now is that those trials, as you rightly indicate, can be paired in such a way that we can get through those in an accelerated fashion. So whatever is required in terms of clinical sites, we can now imply and push those pivotal trials as quickly as possible once we get into those. So that's where I see the advantage of the increased capital power that we've achieved post the Vifor deal.

Our next question comes from Jason Gerberry with Bank of America.

This is Chi on for Jason, thanks for taking my question. Just one from me. On the ongoing atopic dermatitis exercise, curious if you monitor -- actively monitoring interruptions in site visit or dose interruption while the trial ongoing and blinded? And if so, do you have any sense whether you have observed what the data monitor will have popped any interruption in site visit or dose interruption?

Yes, hi, Chi, that's a good question. We actually are using electronic data capture for that particular trial. So we have very detailed information on dosage and when dosage occurs. And so far, we haven't seen any significant interruption issues. In fact, as we've talked about before, in Q2, post the COVID lockdown, we've seen a pretty healthy rebound in enrollment rates in that trial. And we do expect that trial, as I said earlier, to be fully enrolled very soon, this quarter. So, no, we haven't seen any significant dose reduction issues for those patients.

And our next question comes from Alan Carr with Needham & Company.

One, Derek, can you give us a sense of the scale of the -- this open label safety Phase 3 trial that you're going to be starting? What sort of database are you going to need for the oral formulation in total for that? And then a big picture question. Obviously, you've made clear that you plan to look for more indications for Oral KORSUVA, but I'm wondering in the long-term, where do you expect to see Cara where you plan to take it, you plan to bring in other drugs or maybe work within your existing early stage library of compounds?

On the open label trial Alan, we will -- when we start that trial, we'll be releasing details on the size of that trial. And that's when you're going to see everything you've asked in relation to open label. But as we've discussed before, the strategy with CKD pre-dialysis patients for oral KORSUVA is that we feel as though we should have the ability to reference the already established database with IV KORSUVA in CKD patients albeit end stage, I you like, stage V dialysis patients. So can’t give you an answer to that right now, because that's going to come obviously post the end of Phase 2 meaning, but there we'd like to see a reduced overall safety database requirement, by virtue of the ability to reference our already established if you like, IV KORSUVA safety database. So that's our strategy there. And, again, definitively, we'll have some answers to that post the end of Phase 2 meeting, which we're targeting for the first quarter of 2021. And then your general 30,000 foot, where we’ll be going with this. Our first goal is, obviously submit our NDA for KORSUVA Injection for dialysis patients. Second major goal, moving Oral KORSUVA forward with our chosen patient population and to registration trials, getting our first label there. And then expanding upon that, in terms of the Oral KORSUVA application. And then beyond that, if we move that into commercialization, then yes, it makes sense down the road, that we look to augment that, particular timeline related to, if you like dermatologically focused Oral KORSUVA. And that may involve both other formulations of KORSUVA that we might pursue, that would be useful for that patient population. And it may also involve looking at possible in-licensing of, again, therapeutics that makes sense to partner with an oral anti-pruritic. So that's a little further down the road. And not something I could discuss with any sort of certainty right now, it’s not something we haven't thought about. But that comes after we push all forward, get into Phase 3 and make sure we can get that to a label first of all.

And our next question comes from Arlinda Lee with Canaccord.

I just have a quick question on the forthcoming trial design that you might be contemplating for this new undisclosed indication. It sounds like your prior trials in pruritic indication provide a sort of a template. Can you give us the size of an indication of what patient population might be? And well the trials be similar in scope to what you've run before? And will they have similar features, for example, like a pre-specified interim assessment?

So, I think the advantage we have now is, as you've indicated, we've established an effective dose range for Oral KORSUVA and we do understand the compare associated with that and the patients we've looked at. And so, for the new patient population, it’s a pretty accurate estimate of where we need to be in terms of exposure level to hopefully see a signal within that population. So, the design is going to be more on a proof-of-concept type design here to make sure we can get a signal there. Based on if you'd like the dose range and data we've already established both in CKD and we're going to see data from atopic. So that's going to be the general design again. We'll talk about more details when we initiate the trial and talk about that in a little more detail. But the most important thing there is that it's going to allow us to establish efficacy within a different pathology associated with chronic pruritus, which ultimately, I think is going to be useful ammunition if you like in our discussions with the FDA, on eventually getting that broad label. So the design is going to use information we've already claimed from our prior oral trials, in terms of dose range we're going to employ and have we dose there. And it's going to be more in line with seeking signal that since we've already established if you like our appropriate dose range for the Oral KORSUVA.

I apologize, I forgot to mention this is Ben calling in for Arlinda.

I did realize it wasn't Arlinda then….

My last question and I apologize if this has been asked before. But with IV KORSUVA, at what point in the NDA process, will you get an idea of where this may or may not be DEA scheduled?

So obviously, as part of our NDA submission, we will be submitting a specific document that's going to address all the aspects required by the FDA there. So after we submit our document, when we get acceptance of that document, the document has a review period there of a couple of months, where the FDA is going to look at that and decide whether ultimately they're going to recommend drug for scheduling. And then at the end of that review period, if they do recommend a scheduling there, and as you know, we have very strong data that this is a drug that shouldn't be scheduled. And we talked about that on these calls before, it doesn't understand it opioid chemistry. And it doesn't release dopamine in preclinical studies, all the preclinical models indicate is not a highly abusable drug. We run the Human Abuse Liability trial per [CSS] guidelines. We run that against a schedule IV, didn’t look like a schedule IV. So we'll be presenting all that strong evidence, that, that should be a non-scheduled compound, but as FDA to decide that it should be scheduled and the likelihood that they are going to recommend that would be a schedule V, then after that review process there will another review process of three months at DEA to confirm that schedule. So that would come at the end of the of the priority review process.

And I'm showing no further questions in the queue at this time. I'd like to turn the call back to Derek Chalmers for any closing remarks.

Great. Thank you, Jamie. And thank you, everybody, for participating in today's call. I'd also like to thank the Cara team, our study investigators and all the patients to continue to participate in our clinical trials. And we look forward to updating you again very, very soon. So thank you very much everybody for dialing in today and have a good night.

Ladies and gentlemen, thank you for your participation on today's conference. This does conclude your program and you may now disconnect.